Company: AZN
Filing Date: 2025-04-29
Form Type: 6-K
Source: 0001654954-25-004737
Chunk: 14

Company: ASTRAZENECA PLC
Filing Date: 2025-04-29
Form: 6-K
Chunk 14
---
 |    23% |     -1pp | -1pp |
| SG&A expense                     |   -4,492 |            50 |                                         957 |    28 | -3,457 |        1 |    4 |
| - SG&A % of Total Revenue        |      33% |               |                                             |       |    25% |     +1pp | +2pp |
| Total operating expense          |   -7,786 |           113 |                                         967 |    29 | -6,677 |        7 |    9 |
| Other operating income & expense |      113 |             1 |                                           - |     1 |    115 |       79 |   78 |
| Operating profit                 |    3,674 |           122 |                                         975 |    32 |  4,803 |       11 |   12 |
| -Operating                       
 Margin                           |      27% |               |                                             |       |    35% |     +1pp |    - |
| Net finance expense              |     -265 |             - |                                           - |    50 |   -215 |      -12 |  -11 |
| Taxation                         |     -481 |           -28 |                                        -187 |   -18 |   -714 |      -18 |  -18 |
| EPS                              |    $1.88 |         $0.06 |                                       $0.51 | $0.04 |  $2.49 |       21 |   21 |

Profit and Loss drivers

Gross profit

The change in Gross Margin (Reported and Core) in Q1 2025 was impacted by:

- Positive effects from fluctuations in foreign exchange rates. Currency impacts may have a positive or negative impact in future quarters

- Positive effects from changing product mix. The rising contribution of Product Sales with profit sharing arrangements ( Lynparza , Enhertu , Tezspire , Koselugo ) has a negative impact on Gross Margin because AstraZeneca records Product Sales in certain markets and pays away a share of the gross profits to its collaboration partners. The profit share paid to partners is recorded in AstraZeneca's Cost of sales line

- Pricing adjustments, for example to sales reimbursed by the Medicare Part D programme in the US, diluted the gross margin in the first quarter. Some of these adjustments resulted in higher volumes, partially offset